Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on May 13, 2016, covering events occurring on May 11, 2016. The filing primarily addresses Item 5.02 regarding the departure of a senior officer and the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes rather than financial performance metrics.
Material Changes
- Appointment of CFO: Michael Becker was named Chief Financial Officer (Principal Financial and Accounting Officer) effective May 11, 2016. He previously served as Senior Vice President of Finance and Corporate Development since November 2014.
- Departure of Officer: Kulendiran Purushothaman, the former Vice President of Finance (Principal Financial and Accounting Officer), terminated his employment without cause effective May 11, 2016.
Management Commentary, Risks, and Unusual Items
Compensatory Arrangements for Michael Becker:
- Base Salary: $232,000 annually.
- Bonus: Eligible for an executive bonus program with a target of 25% of base salary based on individual and corporate objectives.
- Equity: Received 30,000 stock options (exercise price $15.25) and 20,000 restricted shares. Vesting occurs over four years (25% after one year, then 6.25% quarterly).
- Termination Provisions:
- For Cause: Accrued salary, earned bonuses, and vested benefits only.
- Without Cause: Accrued compensation plus 3 months of base salary and 3 months of health benefits.
- Non-Solicitation: A 24-month restriction on soliciting employees or clients following cessation of employment.
Severance for Kulendiran Purushothaman:
Mr. Purushothaman is entitled to severance consisting of three months of base salary and health benefits pursuant to his employment agreement.
Investor Verification Checklist
- Verify the transition of financial reporting responsibilities from Mr. Purushothaman to Mr. Becker.
- Review the full Employment Agreement (Exhibit 10.1) for complete terms regarding Mr. Becker's compensation and termination rights.
- Confirm the impact of the leadership change on the company's ongoing financial operations and investor relations strategy.
- Check subsequent filings for any updates on the vesting schedule or performance metrics tied to Mr. Becker's bonus.